Oleksandr Sverdlov, PhD
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
Original Research
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
August 6, 2025
Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
Original Research
Efficacy of Citalopram Treatment in Bipolar Depression
January 12, 2021
Antidepressants are widely used to treat bipolar illness, though their effectiveness in this disorder has not been established. This randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of...
